Innovation Ventures

Contact Us
☰
  • Partnering Opportunities
  • Partners
  • Investors
  • Innovators
  • About
  • Subscribe
  • facebookyoutubetwitterpinterest

Refine by

Category
Technology Type
Area of Interest
Stage of Development
Patent Status

Partnering Opportunities


  • Genetics Immunology

    Complement 5a increases inflammation in Hunter Syndrome

    Complement 5a increases inflammation in Hunter Syndrome

  • Pulmonology

    Repurposing Barasertib for Idiopathic Pulmonary Fibrosis

    Repurposing a phase I/II compound (AURKB inhibitor - barasertib) for idiopathic pulmonary fibrosis therapy.

  • Immunology

    CAR-NK Therapy for Lupus

    Human Natural Killer cells expressing chimeric antigen receptor that targets aberrant immune system signaling that is involved in auto-antibody production associated with Systemic Lupus Erythematosus.

  • Neurodegenerative Diseases

    Restoring acid-β-glucosidase activity by non-inhibitory small molecule chaperones

    Restore GCase activity in the brain for Gaucher and Parkinson's

  • Neurology

    Multi-Frequency Encoded Source Imaging

    A new imaging technology to localize and visualize electrical and/or magnetic signals in two or more frequency ranges.

  • Neurology

    Histone Deacetylase 3 Inhibitors for Treating Demyelinating Diseases

    HDAC3 inhibitors enhance myelin repair in white matter injury and demyelinating diseases

  • Pulmonology

    Serum Biomarkers and Algorithm of Lung Decline in Cystic Fibrosis

    Novel serum protein biomarkers and functional data analysis-based algorithm used to develop a predictive test for lung function decline.

  • Infectious Disease

    Bivalent VLP Ebola Vaccine

    Bi-valent spherical virus like particle (VLP) vaccine against Ebola virus.

  • Pulmonology

    Method of Treating Cystic Fibrosis with Src Kinase Inhibitors

    Scientists have shown that src kinase inhibitors are effective at treating CF patients with a frame deletion of F508 in the CFTR gene.

  • Asthma

    Repurposing of Cysteamine for the Treatment of Asthma

    Cysteamine, an FDA approved treatment for cystinosis, has been shown to be an effective oral treatment for steroid resistant asthma including airway hyperresponsiveness (AHR) and airway inflammation.

Next Page

Cincinnati Children’s Innovation Ventures

3333 Burnet Avenue, MLC 7032 Cincinnati, Ohio 45229-3026 | partnering@cchmc.org

© 1999-2023 Cincinnati Children's Hospital Medical Center